Catalyst Trusteeship Limited disclosed the creation of a pledge over 7,538,303 equity shares of Dr. Agarwal's Health Care Limited , representing 2.38% of the issued and paid-up share capital.

The encumbrance was created on August 21, 2026, in favour of Catalyst Trusteeship Limited acting as the onshore security agent for lenders to Hyperion Investments Pte. Ltd.

Pledge Dynamics

The newly pledged shares formed part of a larger block released earlier in August. On August 11, 2026, a pledge over 31,698,303 equity shares was released, with disclosure made on August 13, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to this release, Hyperion Investments had pledged 73,193,988 equity shares under a facility agreement dated March 26, 2024, for a facility aggregating up to USD 100,000,000. The initial disclosure under Regulation 29(1) was made on February 6, 2025.

Current Holding Status

Following the recent creation of encumbrance, the total shares held by the acquirer in the nature of encumbrance stand at 49,033,988. This represents 15.47% of the total share capital and 15.36% of the diluted share capital.

The target company’s total voting capital remains unchanged at 316,983,028 fully paid-up equity shares of INR 1/- each. The total diluted share capital stands at 319,262,876 shares.

What the Numbers Show

The data reveals a net reduction in pledged collateral despite the fresh encumbrance. While 7.54 million shares were newly pledged on August 21, this follows the release of 31.70 million shares just ten days prior. The net effect is a decrease of approximately 24.16 million shares from the peak pledge level of 73.19 million shares established in March 2024. This suggests active management of security cover against the USD 100 million facility rather than an accumulation of new debt exposure.

Claymore Investments (Mauritius) Pte. Ltd. has reduced its stake in Dr. Agarwal's Health Care by selling 1,59,00,000 equity shares on the open market. The transaction, which crossed the 2% disclosure threshold under SEBI regulations on August 12, 2026, marks a significant reduction in the investor's position.

Following the sale, Claymore's shareholding in Dr. Agarwal's Health Care fell to 1,63,96,300 shares, representing 5.17% of the total voting capital. This is a decline from its pre-sale holding of 3,22,96,300 shares, or 10.19%.

Sale Details

The shares were sold through open market transactions. The seller, Claymore Investments, acts in concert with Arvon Investments Pte. Ltd., which did not participate in this specific sale. Arvon's holding remained unchanged at 3,12,75,470 shares (9.87%).

What the Numbers Show

The combined holding of Claymore Investments and its person acting in concert (PAC), Arvon Investments Pte. Ltd., dropped from 20.06% to 15.04% following the transaction. Despite the reduction, the group retains a substantial minority stake in the company, maintaining significant influence without crossing the promoter threshold. No encumbrances or pledges were reported on the shares held by either entity.